MaxCyte, Inc.’s Post

Important news for our development in the US.   The United States Patent and Trademark Office has released a few weeks ago a “Notice of Allowance and Fees Due” relative to one of the 2 patents application regarding the Lung test, “Methods and Compositions for Predicting Chronic Allograft Dysfunction”. 🧪This patent, for which BioMAdvanced Diagnostics has an exclusive licence, covers the use of the expression of 2 specific genes. The USPTO had already granted a 1st patent on the use of expression of 1st gene and this notification is directed to the 2nd gene expression use.   BioMAdvanced Diagnostics intends to pay the requested fees in due time and does not expect any issue preventing the definitive grant. 🚀This is very exciting news, especially in light of further IP developments which we will shortly disclose. 🙏Many thanks to Elise Petit-Rodat and Antoine Vialle from the , to Manon Bonneton from ICOSA and of course Richard Danger for their contribution to this result! #DeepTech #MedTech #Nantes #LaFrenchCare #startup

The #biotech space is cluttered with many companies claiming to be on the cutting edge, with little to back this up. Genflow Biosciences (LON:GENF) (OTCQB:GENFF), on the other hand, stands out in numerous ways. Differentiating between the true innovators and the rest can be difficult. That's why we've created a new fact sheet summarizing our exciting research that aims to extend both human and canine #healthspan. What sets #GENF apart: ✅ Long life IP, protecting our #SIRT6 cenenarian gene & gene delivery research ✅ Creating #NASH treatment to address untapped market of 35 million people ✅ Lead by experienced team with a background running public companies Learn more about Genflow's exciting investment thesis: https://loom.ly/qLRb1jE

Important news for our development in the US.   The United States Patent and Trademark Office has released a few weeks ago a “Notice of Allowance and Fees Due” relative to one of the 2 patents application regarding the Lung test, “Methods and Compositions for Predicting Chronic Allograft Dysfunction”. 🧪This patent, for which BioMAdvanced Diagnostics has an exclusive licence, covers the use of the expression of 2 specific genes. The USPTO had already granted a 1st patent on the use of expression of 1st gene and this notification is directed to the 2nd gene expression use.   BioMAdvanced Diagnostics intends to pay the requested fees in due time and does not expect any issue preventing the definitive grant. 🚀This is very exciting news, especially in light of further IP developments which we will shortly disclose. 🙏Many thanks to Elise Petit-Rodat and Antoine Vialle from the SATT OUEST VALORISATION, to Manon Bonneton from ICOSA and of course Richard Danger for their contribution to this result! #DeepTech #MedTech #Nantes #LaFrenchCare #startup

🚀 Exciting News from the Biotech Frontier! 🧬 CRISPR QC, an innovation leader in gene editing quality control, has just gained a significant boost from Xcellerant Ventures in a Series A funding round! Dive into how their proprietary CRISPR-Chip technology is reshaping the CRISPR landscape with direct, real-time analytics. Get the scoop on their next big move, including a new Arizona satellite office, and see how this infusion of funds will propel their cutting-edge CRISPR Analytics Platform to new heights. Ready for a glimpse into the future of gene editing precision? Check out my latest blog post! #CRISPR #Biotech #Innovation #FundingNews #CRISPRQC #GeneEditing #ScienceTech [Link to the blog post]

Grail founder join forces on new gene editing startup, Moonwalk A new startup co-founded by CRISPR innovator Feng Zhang, a former executive at Grail and Illumina, and others has raised $57 million to develop a defanged form of gene editing that doesn’t cut the DNA strand. Moonwalk Therapeutics launched Thursday with funding from Alpha Wave Ventures, ARCH Venture Partners, Future Ventures, Khosla Ventures, GV, and YK Bioventures. It plans to use that money to develop treatments for a variety of diseases, including chronic and aging-related conditions, using what’s called epigenetic editing. Most of the gene editing technologies being used today slice or nick the DNA strand and make permanent changes to the biological building blocks of genes. Moonwalk, however, plans to alter the activity of genes by focusing on chemical changes. The company is targeting the surrounding chemicals that influence how genes act. This can be done through chemical processes methylation, which turns genes on, or demethylation, which turns genes off. https://lnkd.in/ebjHgDDB

Okay smart #science friends, what do we think? Limula is helping to make cell and gene therapy more affordable & accessible (in theory). I feel like this article (link in comments) doesn’t do a great job of explaining how they’re improving the current processes but maybe you understand/infer more than I do? #genetherapy #startups #venturecapital #biotech

A really outstanding explanation of the concept and application of epigenetics. This is related to, but different than gene editing. You may not be able to access without a subscription to the Wall Street Journal... It ain't cheap, but it's the cheapest MBA program you'll ever enter. Your return on investment will be high. (Yes, I'm a WSJ fanboy....) #epigenetics #Biotech #biotechinnovation Moonwalk Bio Grabs $57 Million, Joins Push for ‘Epigenetic’ Treatments https://lnkd.in/exUr4RbH

#CRISPR pioneer Feng Z. has been cranking out paper after paper on new gene editing enzymes that he's put into a stealth startup Serendipity Bio. Now, his older company Arbor Biotechnologies is acquiring the new startup. Read more in my exclusive story for Endpoints News: This small acquisition says a couple things about the gene editing field: 1. Companies are locking up i.p. to small CRISPR enzymes that may be crucial for prime editing and gene insertion methods 2. Discovering cool new enzymes doesn't guarantee a full-blown $100M+ biotech with its own pipeline anymore https://lnkd.in/exnX2Ujk

Synthego Corporation has announced the divestiture of its engineered cell and CRISPR guide RNA business, forming a standalone entity named EditCo Bio. This independent venture, based in Redwood City, California, has secured investment funding from Telegraph Hill Partners, though the exact amount remains undisclosed. EditCo Bio will concentrate on advancing and producing optimized CRISPR guide RNAs and edited cells primarily for clients engaged in cell biology and gene therapy research. Spearheading this endeavor is CEO John Tan, formerly Synthego's president and COO, alongside CSO Travis Maures, who previously held the position of chief technology officer at Synthego. Maures emphasized the transformative potential of CRISPR in expediting drug discovery processes and enhancing the quality of medications entering clinical trials. He expressed confidence in EditCo's capabilities, citing its successful track record within Synthego as grounds for immediate commercial operations. Meanwhile, Synthego, having raised $200 million approximately two years prior, is redirecting its focus towards therapeutic applications of CRISPR under the leadership of a newly appointed CEO. Don't forget to follow me for all the latest genomics and proteomics news and live roles! #synthego #editco #crispr #genetherapy #biotech

📢Revolutionary AI Drug Discovery Startup Secures £14m Belfast-based techbio company AMPLY Discovery Ltd has received £1.4m in grant funding to advance its AI-based drug discovery platform. The funding will be used to develop new therapies for genetically mediated cancers and multi-drug resistant lung infections. AMPLY aims to use AI and synthetic biology to make drug discovery more predictable and cost-effective. The company is also planning to raise £1.4m in a seed funding round later this year. #BioprocessUpdates #AMPLYDiscovery #funding #techbio #AI #drugdiscovery #geneticallymediatedcancers #lunginfections #syntheticbiology #predictability #costeffectiveness #seedfunding ▷ Read the full article here: 📎 https://lnkd.in/dFUGPwfv